This is a working overview of IGF-1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
== External links == prolyl+endopeptidase,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Prolyl Endopeptidase entry at the National Center for Biotechnology Information PDBe-KB provides an overview of all the structure information available in the PDB for Human Prolyl endopeptidase
{\displaystyle {\begin{aligned}{\frac {\mathbf {D} m}{\mathbf {Dt} }}&={\iiint \limits _{V}}\left({{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )}\right)dV\\{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot {\mathbf {u} })&={\frac {\partial \rho }{\partial t}}+({\nabla \rho })\cdot {\mathbf {u} }+{\rho }(\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+\nabla \cdot ({\rho \mathbf {u} })=0\end{aligned}}}
Rotheca myricoides or Butterfly Clerodendrum, Butterfly Bush, and (butterfly bush – also a name for Buddleja species) is a species of flowering plant in the family Lamiaceae. It is native to tropical eastern Africa and widely cultivated elsewhere. In cultivation, it is frequently known by one of its synonyms, such as Clerodendrum myricoides. The cultivar 'Ugandense' is an untidy evergreen shrub growing to 4 m (13 ft) tall and 2.5 m (8.2 ft) broad, with oval leaves and masses of pale-violet blue butterfly-like flowers in summer and autumn. Each flower has a darker blue lower petal. With a minimum temperature of 10 °C (50 °F), this plant can only be grown under glass in temperate zones. The altitude range for this species is 900–1680 m. The plant has won the Royal Horticultural Society's Award of Garden Merit.
=== Applications in proteomics === In proteomics, the study of the full set of proteins expressed by a genome, identifying diseases biomarkers can involve the usage of stable isotope labeling by amino acids in cell culture (SILAC), that provides isotopic labeled forms of amino acid used to estimate protein levels. In protein recombinant, manipulated proteins are produced in large quantities and isotope labeling is a tool to test for relevant proteins. The method used to be about selectively enrich nuclei with 13C or 15N or deplete 1H from them. The recombinant would be expressed in E.coli with media containing 15N-ammonium chloride as a source of nitrogen. The resulting 15N labeled proteins are then purified by immobilized metal affinity and their percentage estimated. In order to increase the yield of labeled proteins and cut down the cost of isotope labeled media, an alternative procedure primarily increases the cell mass using unlabeled media before introducing it in a minimal amount of labeled media. Another application of isotope labeling would be in measuring DNA synthesis, that is cell proliferation in vitro. Uses H3-thymidine labeling to compare pattern of synthesis (or sequence) in cells.
Sources: en.wikipedia.org
== Composition == Guinness stout is made from water, malted barley, roasted barley, hops, and brewer's yeast. A portion of the barley is roasted to give Guinness its dark colour and characteristic taste. It is pasteurised and filtered. Until the late 1950s, Guinness was still racked into wooden casks. In the late 1950s and early 1960s, Guinness ceased brewing cask-conditioned beers and developed a keg brewing system with aluminium kegs replacing the wooden casks; these were nicknamed "iron lungs". Until 2016 the production of Guinness, as with many beers, involved the use of isinglass made from fish. Isinglass was used as a fining agent for settling out suspended matter in the vat. The isinglass was retained in the floor of the vat but it was possible that minute quantities might be carried over into the beer. Diageo announced in February 2018 that the use of isinglass in draught Guinness was to be discontinued and an alternative clarification agent would be used instead, making the drink acceptable to vegans and vegetarians.
=== Society === Little is revealed of the Combine's activities outside of Earth, but dialogue in Half-Life 2 states that they control worlds of various dimensions inhabited by a range of species. The Combine occupation of Earth is shown to be a brutal totalitarian police state. In City 17, an Eastern European city, Civil Protection units routinely conduct searches of apartment blocks, interrogating human citizens, and engaging in wanton police brutality. The military Overwatch forces of the Combine attack human resistance bases in an effort to further solidify their authority in the urban centers. Human citizens are clad in blue uniforms, living in designated apartment blocks and move around to different cities or locales in passenger trains by the Combine's will. Vortigaunts, enemy alien creatures from Half-Life, have also been enslaved, and are observed in various professions such as janitors. According to Half-Life 2: Raising the Bar, the Combine are draining Earth's oceans and resources to be used on other Combine worlds. The heart of the Combine's command over Earth in Half-Life 2 is the Citadel, a large tower constructed by them which reaches both tens of thousands of feet (several or several tens of kilometres) into the sky and deep underground. Located within City 17, the Citadel serves as the Combine's headquarters on Earth, housing Combine Advisors and the office of Earth's administrator, Dr. Wallace Breen. Breen, a puppet ruler, is frequently seen on large screens around the city on which he spreads propaganda and makes announcements.
This approximation is convenient and applicable with little error in most applications having to deal with pools of hydrogen from natural processes. The maximum difference between the calculated delta (δ) value with the approximate and exact equations is given by the following equation:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.